Doctor of Osteopathy Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Bianca Brunelli

Hospice and Palliative Medicine Phoenix, AZ Doctor of Osteopathy

NPI 1033404553 CMS profile 273608

4611 E Shea Blvd Ste 190, Phoenix, AZ 85028

Open in the dashboard

General payments

$996

36 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Bianca Brunelli of Phoenix, AZ is reported in the CMS Open Payments database as having received $996 across 36 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Hospice and Palliative Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $408 14
2024 General $545 20
2023 General $26 1
2022 General $16 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Bianca Brunelli
  • Hospice and Palliative Medicine median
  • Middle half of Hospice and Palliative Medicine
  • National median

In program year 2025, general payments to Bianca Brunelli were reported at $408. Among 378 Hospice and Palliative Medicine profiles paid that year, the median was $78 and the middle half received between $28 and $160.

Show as a table
Year Bianca Brunelli Hospice and Palliative Medicine median Middle half National median
2019 $0 $80 $22–$147 $163
2020 $0 $36 $18–$121 $114
2021 $0 $64 $23–$194 $132
2022 $16 $67 $22–$158 $149
2023 $26 $65 $25–$149 $160
2024 $545 $75 $25–$158 $164
2025 $408 $78 $28–$160 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Medtronic, Inc. $341 8 payments
  2. Protega Pharmaceutials LLC $153 4 payments
  3. Salix Pharmaceuticals, a division of Bausch Health US, LLC $120 6 payments
  4. TerSera Therapeutics LLC $84 3 payments
  5. Vertex Pharmaceuticals Incorporated $69 3 payments
  6. AbbVie, Inc. $65 3 payments
  7. Pfizer Inc. $46 3 payments
  8. Valinor Pharma, LLC $41 2 payments
  9. Jazz Pharmaceuticals Inc. $26 1 payment
  10. Piramal Critical Care $18 1 payment
  11. Other $33 2 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $996 36 payments
Products named General payments · program years 2022–2025
  1. SYNCHROMEDII $238 7 payments
  2. ROXYBOND $153 4 payments
  3. RELISTOR Gastroenterology $120 6 payments
  4. RELISTOR Gastroenterology $120 6 payments
  5. INCEPTIV $103 1 payment
  6. Prialt $84 3 payments
  7. QULIPTA $65 3 payments
  8. UBRELVY $48 2 payments
  9. NURTEC ODT $46 3 payments
  10. ZAVZPRET $46 3 payments
  11. Other $231 12 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 29 drugs

Part D claims

1,357

Median for Hospice and Palliative Care: 260

Drug cost

$97,538

Median for Hospice and Palliative Care: $10,445

Branded share of claims

23.4%

Median for Hospice and Palliative Care: 16.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xtampza Er Oxycodone Myristate Brand 47 $39,386
Buprenorphine Generic 71 $12,101
Belbuca Buprenorphine Hcl Brand 19 $11,925
Fentanyl Generic 71 $10,693
Oxycodone Hcl Generic 293 $6,206
Morphine Sulfate Er Morphine Sulfate Brand 98 $2,931
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 76 $1,633
Gabapentin Generic 123 $1,580
Morphine Sulfate Generic 48 $1,543
Pregabalin Generic 61 $1,446

The 10 drugs with the highest cost, of 29 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,124 Part D prescribers listed as Hospice and Palliative Care; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 46 billing codes

Paid by Medicare

$233,995

Of which drugs: $17,764

Medicare patients

371

Average age 71

Services billed

32,429

224 women, 147 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 73%
Arthritis 66%
Depression 47%
Ischemic heart disease 32%
Chronic kidney disease 32%
Cancer 30%
COPD 28%
Diabetes 27%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 25 124 $95

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 10 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ROXYBOND
  • PROTEGA PHARMACEUTIALS LLC $90
$90 — —
RELISTOR
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $40
$40 — —
Prialt
  • TerSera Therapeutics LLC $25
$25 — —
NURTEC ODT
  • PFIZER INC. $23
$23 — —
ZAVZPRET
  • PFIZER INC. $23
$23 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 10 in the dashboard with a free account

Records

36 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Hospice and Palliative Medicine in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record